Allovate - Model OMIT - Oral Mucosal Immunotherapy

Oral mucosal immunotherapy (OMIT) is a novel form of allergen-specific immunotherapy. Immunotherapy has a 100-year track record of success for respiratory allergies. OMIT improves upon this approach by delivering immunotherapeutic agents to the areas of the oral cavity with the highest likelihood of prompting a decrease in allergy symptoms in order to improve the health of allergy sufferers. Clinical investigations led by Allovate are developing the OMIT platform for the treatment of respiratory allergies to environmental substances like dust mite, pollen, animal dander, and molds. OMIT offers the potential of a long-term solution for more than 60 million Americans and more than 200 million people worldwide who have allergies.